GB202108543D0 - Compounds and their use for the treatment of alpha1-antitrypsin deficiency - Google Patents

Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Info

Publication number
GB202108543D0
GB202108543D0 GBGB2108543.6A GB202108543A GB202108543D0 GB 202108543 D0 GB202108543 D0 GB 202108543D0 GB 202108543 A GB202108543 A GB 202108543A GB 202108543 D0 GB202108543 D0 GB 202108543D0
Authority
GB
United Kingdom
Prior art keywords
alpha1
compounds
treatment
antitrypsin deficiency
antitrypsin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2108543.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Z Factor Ltd
Original Assignee
Z Factor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Z Factor Ltd filed Critical Z Factor Ltd
Priority to GBGB2108543.6A priority Critical patent/GB202108543D0/en
Publication of GB202108543D0 publication Critical patent/GB202108543D0/en
Priority to PCT/GB2022/051505 priority patent/WO2022263819A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
GBGB2108543.6A 2021-06-15 2021-06-15 Compounds and their use for the treatment of alpha1-antitrypsin deficiency Ceased GB202108543D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2108543.6A GB202108543D0 (en) 2021-06-15 2021-06-15 Compounds and their use for the treatment of alpha1-antitrypsin deficiency
PCT/GB2022/051505 WO2022263819A1 (en) 2021-06-15 2022-06-15 Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2108543.6A GB202108543D0 (en) 2021-06-15 2021-06-15 Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Publications (1)

Publication Number Publication Date
GB202108543D0 true GB202108543D0 (en) 2021-07-28

Family

ID=76954612

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2108543.6A Ceased GB202108543D0 (en) 2021-06-15 2021-06-15 Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Country Status (2)

Country Link
GB (1) GB202108543D0 (en)
WO (1) WO2022263819A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113542A2 (en) * 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
EP2280001B1 (en) * 2008-04-24 2014-10-15 Msd K.K. Long-chain fatty acid elongation enzyme inhibitor comprising arylsulfonyl derivative as active ingredient
WO2010123139A1 (en) * 2009-04-24 2010-10-28 持田製薬株式会社 Arylcarboxamide derivative having sulfamoyl group
TW201819361A (en) * 2016-09-03 2018-06-01 印度商托仁特生技有限公司 Novel indazole compounds
GB201820450D0 (en) * 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
TW202116303A (en) * 2019-10-02 2021-05-01 美商維泰克斯製藥公司 Methods of treatment for alpha-1 antitrypsin deficiency

Also Published As

Publication number Publication date
WO2022263819A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
ZA202103977B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
IL288061A (en) Compounds and methods for the treatment of covid-19
ZA202207493B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918413D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918414D0 (en) Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918404D0 (en) Compounds and their use for the treatment of aplha1-antitrypsin deficiency
GB202108543D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108542D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108544D0 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
IL309172A (en) Valbenazine for use in the add-on treatment of schizophrenia
GB202217355D0 (en) Methods for the prophylaxis and treatment of Covid and Covid-19
GB201918416D0 (en) Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
GB202108523D0 (en) Compositions and their use for the treatment of alpha1-antitrypsin deficiency
IL282718A (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
EP4100127A4 (en) Methods for the treatment of scleroderma and related conditions
IL276228A (en) Compounds and compositions for the treatment of pain
GB201820451D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201820455D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB201820452D0 (en) Compounds and their use for the treatment of alpha1-antitryspin deficiency
GB2610895B (en) Composition for use in the treatment and/or prevention of mycotoxic disease
EP4117787A4 (en) Agents and compositions for the treatment of glioblastoma
GB202019762D0 (en) Compounds for use in treatment and prophylaxis
GB201918539D0 (en) Compounds for use in treatment and prophylaxis
GB202302121D0 (en) Compounds for use in the treatment of schizophrenia

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)